Aimmune Therapeutics to Participate in Three Investor Conferences in September
September 06 2017 - 8:00AM
Business Wire
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical
company developing treatments for life-threatening food allergies,
today announced that members of the Aimmune executive management
team will be presenting at three upcoming investor conferences in
September.
Event: BioCentury NewsMakers in the Biotech
IndustryDate: Friday, September 8, 2017Time: 11:00
a.m. Eastern TimeLocation: New YorkPresenter: CFO
Eric Bjerkholt
Event: Bank of America Merrill Lynch Global Healthcare
ConferenceDate: Friday, September 15, 2017Time: 10:40
a.m. British Summer TimeLocation: LondonPresenter:
CEO Stephen Dilly, M.B.B.S., Ph.D.
Event: Cantor Fitzgerald Global Healthcare
ConferenceDate: Tuesday, September 26, 2017Time: 9:10
a.m. Eastern TimeLocation: New YorkPresenter: CFO
Eric Bjerkholt
Live webcasts of the presentations will be accessible on the
Events page under the Investor Relations section of the Aimmune
website at www.aimmune.com. Replays of the webcasts will be
available for at least 30 days following each webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage
biopharmaceutical company developing treatments for
life-threatening food allergies. The company’s Characterized Oral
Desensitization ImmunoTherapy (CODIT™) approach is intended to
achieve meaningful levels of protection by desensitizing patients
with defined, precise amounts of key allergens. Aimmune’s first
investigational biologic product using CODIT™, AR101 for the
treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic
patients 4-17 years of age and is currently being evaluated in
Phase 3 clinical trials. For more information, please see
www.aimmune.com.
This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by
the U.S. Food and Drug Administration (FDA) or the European
Medicines Agency (EMA). It is currently limited to investigational
use, and no representation is made as to its safety or
effectiveness for the purposes for which it is being
investigated.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170906005590/en/
Aimmune Therapeutics, Inc.InvestorsLaura Hansen, Ph.D.,
650-396-3814lhansen@aimmune.comorMediaStephanie Yao,
650-351-6479syao@aimmune.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Apr 2023 to Apr 2024